San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron ...

Regeneron Pharmaceuticals Inc. closed 43.47% below its 52-week high of $1,211.20, which the company achieved on August 27th.

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

Regeneron Pharmaceuticals Inc. closed 44.20% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

Alaina Pinto of The Wheatley School in East Williston School District was announced as one of the top 300 scholars from ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target cut by research analysts at Piper Sandler from $1,195.00 to $1,013.00 in a report issued on Monday,Benzinga reports. The ...